JP2016028081A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016028081A5 JP2016028081A5 JP2015179993A JP2015179993A JP2016028081A5 JP 2016028081 A5 JP2016028081 A5 JP 2016028081A5 JP 2015179993 A JP2015179993 A JP 2015179993A JP 2015179993 A JP2015179993 A JP 2015179993A JP 2016028081 A5 JP2016028081 A5 JP 2016028081A5
- Authority
- JP
- Japan
- Prior art keywords
- invention described
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76097406P | 2006-01-19 | 2006-01-19 | |
| US60/760,974 | 2006-01-19 | ||
| US11/544,389 | 2006-10-06 | ||
| US11/544,389 US8168584B2 (en) | 2005-10-08 | 2006-10-06 | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013086862A Division JP2013155189A (ja) | 2006-01-19 | 2013-04-17 | 眼の障害のための注射可能複合療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016028081A JP2016028081A (ja) | 2016-02-25 |
| JP2016028081A5 true JP2016028081A5 (enExample) | 2016-05-19 |
Family
ID=38179525
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551458A Pending JP2009523821A (ja) | 2006-01-19 | 2007-01-19 | 眼の障害のための注射可能複合療法 |
| JP2013086862A Pending JP2013155189A (ja) | 2006-01-19 | 2013-04-17 | 眼の障害のための注射可能複合療法 |
| JP2015179993A Pending JP2016028081A (ja) | 2006-01-19 | 2015-09-11 | 眼の障害のための注射可能複合療法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008551458A Pending JP2009523821A (ja) | 2006-01-19 | 2007-01-19 | 眼の障害のための注射可能複合療法 |
| JP2013086862A Pending JP2013155189A (ja) | 2006-01-19 | 2013-04-17 | 眼の障害のための注射可能複合療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US8168584B2 (enExample) |
| EP (1) | EP1993673B1 (enExample) |
| JP (3) | JP2009523821A (enExample) |
| AU (2) | AU2007207385B2 (enExample) |
| DK (1) | DK1993673T3 (enExample) |
| ES (1) | ES2644752T3 (enExample) |
| PL (1) | PL1993673T3 (enExample) |
| WO (1) | WO2007084765A2 (enExample) |
Families Citing this family (137)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| US8246569B1 (en) | 2004-08-17 | 2012-08-21 | California Institute Of Technology | Implantable intraocular pressure drain |
| US8043609B2 (en) | 2004-10-08 | 2011-10-25 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| WO2006042252A2 (en) * | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| WO2007106557A2 (en) | 2006-03-14 | 2007-09-20 | University Of Southern California | Mems device for delivery of therapeutic agents |
| AU2007237096C1 (en) | 2006-04-07 | 2012-12-13 | EyePoint, Inc. | Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US20080089923A1 (en) | 2006-09-29 | 2008-04-17 | Burkstrand Michael J | Biodegradable ocular implants and methods for treating ocular conditions |
| EP2083841B1 (en) * | 2006-10-20 | 2013-11-20 | Celldex Therapeutics, Inc. | SOLUBLE COMPLEMENT RECEPTOR TYPE I (sCR1) PROTEIN FOR USE IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER DISEASES OF THE EYE |
| AU2008214359B2 (en) * | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| WO2009015087A2 (en) * | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
| CN101854916A (zh) * | 2007-10-02 | 2010-10-06 | 博泰迪亚制药公司 | 由凝胶持续递送坎普他汀类似物 |
| MX364408B (es) * | 2007-12-20 | 2019-04-25 | Univ Southern California | Aparatos y metodos para suministrar agentes terapeuticos. |
| US20090192493A1 (en) | 2008-01-03 | 2009-07-30 | University Of Southern California | Implantable drug-delivery devices, and apparatus and methods for refilling the devices |
| US8521273B2 (en) | 2008-01-29 | 2013-08-27 | Gilbert H. KLIMAN | Drug delivery devices, kits and methods therefor |
| US8481508B2 (en) * | 2008-02-21 | 2013-07-09 | University Of Kentucky Research Foundation | Ultra-small RNAs as toll-like receptor-3 antagonists |
| WO2009105534A2 (en) * | 2008-02-21 | 2009-08-27 | Ista Pharmaceuticals | Ophthalmic nsaids as adjuvants |
| EP2278987A4 (en) * | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| ES2338400B1 (es) * | 2008-05-06 | 2011-09-14 | David Benet Ferrus | Conjunto de moleculas antiangiogenicas y su uso. |
| US8348897B2 (en) | 2008-05-08 | 2013-01-08 | Minipumps, Llc | Implantable drug-delivery devices, and apparatus and methods for filling the devices |
| EP2320989B1 (en) | 2008-05-08 | 2015-03-11 | MiniPumps, LLC | Implantable pumps and cannulas therefor |
| US8231608B2 (en) | 2008-05-08 | 2012-07-31 | Minipumps, Llc | Drug-delivery pumps and methods of manufacture |
| US9333297B2 (en) | 2008-05-08 | 2016-05-10 | Minipumps, Llc | Drug-delivery pump with intelligent control |
| US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
| CA2723588A1 (en) | 2008-05-12 | 2009-11-19 | University Of Utah Research Foundation | Intraocular drug delivery device and associated uses |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| SG2014007389A (en) | 2009-01-29 | 2014-04-28 | Forsight Vision4 Inc | Posterior segment drug delivery |
| WO2010093945A2 (en) | 2009-02-13 | 2010-08-19 | Glaukos Corporation | Uveoscleral drug delivery implant and methods for implanting the same |
| GB0904427D0 (en) | 2009-03-13 | 2009-04-29 | Lachmann Peter | Treatment of diseases related to hyperactivity of the complement system |
| US20120244192A1 (en) * | 2009-04-27 | 2012-09-27 | Cook Gary P | Sustained release formulations of peptidomimetic drugs and uses thereof |
| NO2424557T3 (enExample) * | 2009-05-01 | 2018-03-24 | ||
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| CA2979355C (en) | 2009-05-18 | 2023-02-21 | Dose Medical Corporation | Drug eluting ocular implant |
| US12478503B2 (en) | 2009-05-18 | 2025-11-25 | Glaukos Corporation | Implants with controlled drug delivery features and methods of using same |
| GB2470378A (en) * | 2009-05-20 | 2010-11-24 | Univ Westminster | A controlled release composition for intraocular delivery of a therapeutic agent |
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| KR101697388B1 (ko) | 2009-08-18 | 2017-01-17 | 미니펌프스, 엘엘씨 | 적응 제어기를 갖춘 전해 약품 운반 펌프 |
| TWI492769B (zh) * | 2009-09-23 | 2015-07-21 | Alcon Res Ltd | 可注射的水性眼用組成物及其使用之方法 |
| WO2013022801A1 (en) | 2011-08-05 | 2013-02-14 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| CA2791278C (en) | 2010-02-25 | 2015-11-24 | The Johns Hopkins University | Sustained delivery of therapeutic agents to an eye compartment |
| WO2011135400A1 (en) * | 2010-04-30 | 2011-11-03 | Indian Institute Of Technology Bombay | Nanoparticulate in-situ gels as vitreous humor substitutes for ocular diseases |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| US20130324482A1 (en) * | 2010-07-09 | 2013-12-05 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
| HRP20211909T1 (hr) * | 2010-08-05 | 2022-03-18 | Forsight Vision4, Inc. | Uređaj za liječenja oka |
| EP2600920A4 (en) * | 2010-08-05 | 2017-10-04 | Forsight Vision4, Inc. | Subconjunctival implant for posterior segment drug delivery |
| US9033911B2 (en) | 2010-08-05 | 2015-05-19 | Forsight Vision4, Inc. | Injector apparatus and method for drug delivery |
| CA2807537C (en) | 2010-08-05 | 2018-09-18 | Forsight Vision4, Inc. | Combined drug delivery methods and apparatus |
| US20140031769A1 (en) | 2010-11-19 | 2014-01-30 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| EP2654715B1 (en) | 2010-11-24 | 2017-01-25 | Dose Medical Corporation | Drug eluting ocular implant |
| US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
| WO2012109363A2 (en) | 2011-02-08 | 2012-08-16 | The Johns Hopkins University | Mucus penetrating gene carriers |
| US9603997B2 (en) | 2011-03-14 | 2017-03-28 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US9919099B2 (en) | 2011-03-14 | 2018-03-20 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| US10286146B2 (en) | 2011-03-14 | 2019-05-14 | Minipumps, Llc | Implantable drug pumps and refill devices therefor |
| CN107050422B (zh) | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
| US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
| EP4249059B1 (en) | 2011-06-28 | 2025-07-30 | ForSight Vision4, Inc. | An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye |
| EP4643921A3 (en) | 2011-09-16 | 2026-01-07 | ForSight Vision4, Inc. | Fluid exchange apparatus |
| EP2766043A4 (en) | 2011-10-13 | 2015-06-10 | Aerpio Therapeutics Inc | METHOD FOR THE TREATMENT OF CAPILLARY LECKSYNDROME AND CANCER |
| KR20210021112A (ko) | 2011-11-18 | 2021-02-24 | 리제너론 파마슈티칼스 인코포레이티드 | 폴리머 단백질 미립자 |
| ES2651521T3 (es) | 2011-12-01 | 2018-01-26 | Innovent Biologics, Inc. | Inhibidores proteicos de las rutas del complemento y de VEGF y métodos de uso de los mismos |
| BR112014016640A2 (pt) * | 2012-01-04 | 2021-03-16 | Quark Pharmaceuticals Inc | composto de rna de fita dupla para casp2 e seus usos |
| US10010448B2 (en) | 2012-02-03 | 2018-07-03 | Forsight Vision4, Inc. | Insertion and removal methods and apparatus for therapeutic devices |
| JP5883539B2 (ja) | 2012-03-16 | 2016-03-15 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Ｈｉｆ−１阻害剤の送達のための放出制御製剤 |
| EA030318B1 (ru) | 2012-03-16 | 2018-07-31 | Дзе Джонс Хопкинс Юниверсити | Конъюгаты нелинейного мультиблочного сополимера с лекарственным средством для доставки активных агентов |
| US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
| AU2013100070B4 (en) * | 2012-07-03 | 2013-04-04 | Novartis Ag | Use of device |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| PT3660033T (pt) | 2012-11-15 | 2021-07-06 | Apellis Pharmaceuticals Inc | Análogos de compstatina de longa ação e composições e métodos relacionados |
| US20160194359A1 (en) * | 2012-11-15 | 2016-07-07 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| US9597227B2 (en) | 2013-03-15 | 2017-03-21 | Abbott Medical Optics Inc. | Trans-sclera portal for delivery of therapeutic agents |
| US10308687B2 (en) | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| WO2014160884A1 (en) | 2013-03-28 | 2014-10-02 | Forsight Vision4, Inc. | Ophthalmic implant for delivering therapeutic substances |
| US9968623B2 (en) * | 2013-08-29 | 2018-05-15 | Lanny Leo Johnson | Prepackaged sterile syringe or containers with various substance concentrations with or without bioactive reagent |
| US9655862B2 (en) * | 2013-10-29 | 2017-05-23 | Shaker A. Mousa | Ocular nanoformulation and method of use in angiogenesis-mediated disorders |
| WO2015184173A1 (en) | 2014-05-29 | 2015-12-03 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| EP3166550B1 (en) | 2014-07-11 | 2023-12-13 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Surgical tool for ocular tissue transplantation |
| RU2695563C2 (ru) | 2014-07-15 | 2019-07-24 | Форсайт Вижн4, Инк. | Способ и устройство для доставки глазного имплантата |
| JP2017524034A (ja) | 2014-08-08 | 2017-08-24 | フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． | 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法 |
| KR20170106298A (ko) | 2014-11-10 | 2017-09-20 | 포사이트 비젼4, 인크. | 확장 가능한 약물 전달 장치 및 이용 방법 |
| KR20240126072A (ko) | 2015-01-27 | 2024-08-20 | 더 존스 홉킨스 유니버시티 | 점막표면에서 활성제의 향상된 수송을 위한 저장성 하이드로겔 제제 |
| WO2017035409A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| RU2770099C2 (ru) | 2015-10-07 | 2022-04-14 | Апеллис Фармасьютикалс, Инк. | Схемы введения |
| EP3377009B1 (en) | 2015-11-20 | 2020-10-28 | ForSight Vision4, Inc. | Porous structures for extended release drug delivery devices |
| CA3137326C (en) | 2015-12-03 | 2024-01-23 | Regeneron Pharmaceuticals, Inc. | Use of vegf inhibitor to treat macular degeneration in a patient population |
| EP3405577B8 (en) * | 2016-01-20 | 2023-02-15 | 396419 B.C. Ltd. | Compositions and methods for inhibiting factor d |
| KR20180128941A (ko) * | 2016-03-31 | 2018-12-04 | 오메로스 코포레이션 | 혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법 |
| CN113017981B (zh) | 2016-04-05 | 2023-07-25 | 弗赛特影像4股份有限公司 | 药物递送装置 |
| CA3022830A1 (en) | 2016-04-20 | 2017-10-26 | Harold Alexander Heitzmann | Bioresorbable ocular drug delivery device |
| EP3562512B1 (en) * | 2016-11-28 | 2024-11-27 | Indian Institute Of Technology, Delhi | A formulation for stabilizing bio-therapeutics |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| EP3582756A1 (en) * | 2017-02-16 | 2019-12-25 | Yeda Research and Development Co., Ltd. | Liposomic drug-delivery vehicles |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| EP3589287B1 (en) | 2017-03-01 | 2022-09-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for treatment of medical disorders |
| FI3985002T3 (fi) | 2017-03-01 | 2025-07-30 | Achillion Pharmaceuticals Inc | Aryyli-, heteroaryyli- ja heterosyklisiä lääkeyhdisteitä sairauksien hoitoon |
| US11040107B2 (en) | 2017-04-07 | 2021-06-22 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| WO2019014280A1 (en) * | 2017-07-11 | 2019-01-17 | Sustained Nano Systems Llc | HYDRO-PRESSED PHARMACEUTICAL FORMULATIONS |
| US20190038623A1 (en) | 2017-08-02 | 2019-02-07 | Achillion Pharmaceuticals, Inc. | Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria |
| IT201700101582A1 (it) * | 2017-09-12 | 2019-03-12 | Milano Politecnico | Dispositivo per rilascio intraoculare |
| CN111372950B (zh) | 2017-10-12 | 2024-11-05 | 免疫苏醒公司 | Vegfr-抗体轻链融合蛋白 |
| EP3713528A1 (en) | 2017-11-21 | 2020-09-30 | ForSight Vision4, Inc. | Fluid exchange apparatus for expandable port delivery system and methods of use |
| MA51162A (fr) | 2017-12-15 | 2020-10-21 | Apellis Pharmaceuticals Inc | Schémas posologiques et compositions et procédés associés |
| CN112105638A (zh) | 2018-04-03 | 2020-12-18 | 恩格姆生物制药公司 | C3结合剂及其使用方法 |
| JP7423070B2 (ja) * | 2018-04-06 | 2024-01-29 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 増加した溶解度および改善された薬物動態特性を有するコンプスタチンアナログ |
| KR102130038B1 (ko) * | 2018-05-17 | 2020-07-03 | (주)올리브바이오테라퓨틱스 | Ccn5를 유효성분으로 포함하는 망막질환 예방 또는 치료용 약학 조성물 |
| US11519020B2 (en) | 2018-05-25 | 2022-12-06 | Regeneron Pharmaceuticals, Inc. | Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF |
| JP7538113B2 (ja) | 2018-08-20 | 2024-08-21 | アキリオン ファーマシューティカルズ，インコーポレーテッド | 補体ｄ因子の医学的障害の治療のための医薬化合物 |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| CN112839945A (zh) | 2018-09-06 | 2021-05-25 | 艾其林医药公司 | 补体因子d抑制剂的形态形式 |
| MX2021003425A (es) | 2018-09-25 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| AU2019406830A1 (en) | 2018-12-17 | 2021-07-08 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| EP3941462A4 (en) | 2019-03-22 | 2023-04-05 | Achillion Pharmaceuticals, Inc. | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES |
| US12496279B2 (en) | 2019-04-11 | 2025-12-16 | The Johns Hopkins University | Nanoparticles for drug delivery to brain |
| AU2020264969B2 (en) | 2019-04-29 | 2025-06-05 | EyePoint, Inc. | Tie-2 activators targeting the schlemm's canal |
| US20220211654A1 (en) * | 2019-05-06 | 2022-07-07 | The Regents Of The University Of California | Materials and methods for treating age-related macular degeneration |
| WO2021011927A1 (en) * | 2019-07-18 | 2021-01-21 | Apellis Pharmaceuticals, Inc. | Complement inhibitor dosing regimens |
| CN115362162A (zh) | 2020-02-20 | 2022-11-18 | 艾其林医药公司 | 用于治疗补体因子d介导的障碍的杂芳基化合物 |
| WO2021247900A1 (en) * | 2020-06-05 | 2021-12-09 | Occurx Pty. Ltd. | Compounds and methods for the treatment of eye disorders |
| US20250171423A1 (en) | 2020-09-23 | 2025-05-29 | Achillion Pharmaceuticals, Inc. | Pharmaceutical compounds for the treatment of complement mediated disorders |
| USD1033637S1 (en) | 2022-01-24 | 2024-07-02 | Forsight Vision4, Inc. | Fluid exchange device |
| WO2024015981A2 (en) * | 2022-07-14 | 2024-01-18 | Character Biosciences, Inc. | Therapeutic compositions and methods for age-related macular degeneration |
| CN120359233A (zh) | 2022-11-24 | 2025-07-22 | 阿麦达斯制药美国有限责任公司 | 用于基于载体的疗法的坎普他汀类似物 |
| WO2025176847A1 (en) | 2024-02-21 | 2025-08-28 | Ags Therapeutics Sas | Ocular delivery of active agents via microalgae extracellular vesicles |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2295746A1 (fr) | 1974-12-23 | 1976-07-23 | Francaise Coop Pharma | Nouveaux derives du tryptophane a activite nerveuse centrale renforcee |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IT1179866B (it) | 1984-12-12 | 1987-09-16 | Rotta Research Lab | Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono |
| US4576750A (en) | 1985-04-22 | 1986-03-18 | Merck & Co., Inc. | Tryptophan derivative |
| US5157110A (en) | 1988-08-20 | 1992-10-20 | The Government Of The United States Of America | Synthetic, anti-complement protein |
| IL95942A0 (en) | 1989-10-13 | 1991-07-18 | Syntex Inc | Collagen-containing ophthalmic formulation |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| US6582959B2 (en) * | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| EP1413587A2 (en) | 1991-05-03 | 2004-04-28 | Washington University | Modified complement system regulator |
| US5492135A (en) | 1992-09-09 | 1996-02-20 | Devore; Dale P. | Collagen modulators for use in photoablation excimer laser keratectomy |
| US5482135A (en) | 1993-06-29 | 1996-01-09 | Deere & Company | Combined hydraulic reservoir and vehicle axle |
| WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
| US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
| US5470952A (en) | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| US5776970A (en) | 1994-04-28 | 1998-07-07 | Yeda Research And Development Co. Ltd. | Tryptophan derivatives as protein tyrosine kinase blockers and their use in the treatment of neoplastic diseases |
| IL117645A (en) * | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| JPH08280800A (ja) * | 1995-04-12 | 1996-10-29 | Nissho Corp | ２液注射用プレフィルドシリンジ |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6129761A (en) | 1995-06-07 | 2000-10-10 | Reprogenesis, Inc. | Injectable hydrogel compositions |
| US6346398B1 (en) | 1995-10-26 | 2002-02-12 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
| AU2203197A (en) | 1996-03-13 | 1997-10-01 | Trustees Of The University Of Pennsylvania, The | Novel peptides which inhibit complement activation |
| US6299895B1 (en) | 1997-03-24 | 2001-10-09 | Neurotech S.A. | Device and method for treating ophthalmic diseases |
| US5843778A (en) | 1996-06-14 | 1998-12-01 | The Johns Hopkins University School Of Medicine | Use of chimeric vaccinia virus complement control proteins to inhibit complement |
| JPH1087700A (ja) | 1996-06-17 | 1998-04-07 | Smithkline Beecham Corp | Ｃ３ａ受容体およびＣ３ａを用いる治療およびスクリーニング方法 |
| US5797898A (en) | 1996-07-02 | 1998-08-25 | Massachusetts Institute Of Technology | Microchip drug delivery devices |
| US6051698A (en) * | 1997-06-06 | 2000-04-18 | Janjic; Nebojsa | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
| AUPO755097A0 (en) | 1997-06-25 | 1997-07-17 | University Of Queensland, The | Receptor agonist and antagonist |
| US6169057B1 (en) | 1997-09-04 | 2001-01-02 | The Regents Of The University Of California | Use of tryptophan and analogs as plant growth regulators |
| WO1999013899A1 (en) | 1997-09-17 | 1999-03-25 | Trustees Of The University Of Pennsylvania | Peptides and peptidomimetics for inhibiting complement activation |
| US8088386B2 (en) | 1998-03-20 | 2012-01-03 | Genentech, Inc. | Treatment of complement-associated disorders |
| JPH11197234A (ja) | 1998-01-09 | 1999-07-27 | Koken Co Ltd | 眼科用コラーゲンゲル成形物 |
| US7112327B2 (en) | 1998-02-20 | 2006-09-26 | Tanox, Inc. | Inhibition of complement activation |
| WO1999044625A1 (en) | 1998-03-03 | 1999-09-10 | John Hopkins University | Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation |
| WO1999052539A1 (en) | 1998-04-10 | 1999-10-21 | Mayo Foundation For Medical Education And Research | Neo-tryptophan |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US7084106B1 (en) | 1999-01-19 | 2006-08-01 | University Of Louisville Research Foundation, Inc. | Application of a viral complement inhibitory protein in the treatment and diagnosis of Alzheimer's Disease |
| EP1154734B1 (en) | 1999-02-12 | 2014-10-01 | ProChon Biotech Ltd. | Injectable collagen-based system for delivery of cells |
| US20020102581A1 (en) | 1999-02-19 | 2002-08-01 | Hageman Gregory S. | Diagnostics and therapeutics for ocular disorders |
| US7108982B1 (en) | 1999-02-19 | 2006-09-19 | University Of Iowa Research Foundation | Diagnostics and the therapeutics for macular degeneration |
| AU5158000A (en) | 1999-05-25 | 2000-12-12 | King Faisal Specialist Hospital And Research Centre | Novel therapeutic use of viral inflammation modulatory protein in blocking xenograft rejection |
| US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| GB9930659D0 (en) | 1999-12-24 | 2000-02-16 | Bio Discovery Ltd | Inhibitors of complement activation |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US7011952B2 (en) | 2000-02-22 | 2006-03-14 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| EP1309726B2 (en) | 2000-03-30 | 2018-10-03 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
| JP4764590B2 (ja) | 2000-04-29 | 2011-09-07 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 黄班変性関連疾患の診断および治療 |
| US6692759B1 (en) | 2000-06-28 | 2004-02-17 | The Regents Of The University Of California | Methods for preparing and using implantable substance delivery devices |
| WO2002011793A1 (fr) * | 2000-08-08 | 2002-02-14 | Medical Information Services, Inc. | Seringue pour preparation de necessaire d'injection, valve coulissante intermediaire pour seringues et preparation de necessaire d'injection |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| ES2483991T3 (es) | 2000-10-10 | 2014-08-08 | Genentech, Inc. | Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II |
| CZ302719B6 (cs) | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| US6976982B2 (en) | 2001-01-09 | 2005-12-20 | Microchips, Inc. | Flexible microchip devices for ophthalmic and other applications |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| US20050054596A1 (en) | 2001-11-30 | 2005-03-10 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
| JP2005511576A (ja) * | 2001-11-09 | 2005-04-28 | アイテック・ファーマシューティカルズ | 眼球血管新生病を治療する方法 |
| EP1453546A2 (en) | 2001-12-04 | 2004-09-08 | Nanospectra Biosciences, Inc. | Treatment of angiogenesis disorders using targeted nanoparticles |
| US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
| AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| AU2003276131A1 (en) | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
| JP3976635B2 (ja) * | 2002-08-05 | 2007-09-19 | 久光製薬株式会社 | キット製剤用注射器、注射器型キット製剤用中間摺動弁、及び、注射器型キット製剤、並びにｘ線造影剤キット製剤 |
| EP2311480B1 (en) * | 2002-09-20 | 2013-06-26 | The Trustees of The University of Pennsylvania | Compstatin analogs with improved activity |
| US7541032B2 (en) | 2002-09-20 | 2009-06-02 | Stichting Katholieke Universiteit | Antigen uptake receptor for Candida albicans on dendritic cells |
| US20060251621A1 (en) | 2002-09-27 | 2006-11-09 | Campochiaro Peter A | Ocular gene therapy |
| EP1553993B1 (en) | 2002-10-21 | 2016-03-30 | Allvivo, Inc. | Surface coating comprising bioactive compound |
| US7595430B2 (en) | 2002-10-30 | 2009-09-29 | University Of Kentucky Research Foundation | Methods and animal model for analyzing age-related macular degeneration |
| US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| JP2006518750A (ja) * | 2003-02-21 | 2006-08-17 | リクスホスピタレット−ラジウムホスピタレット・ホーエフ | 胎便吸引症候群の治療のための方法および組成物 |
| WO2004075837A2 (en) * | 2003-02-21 | 2004-09-10 | Tanox, Inc. | Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury |
| US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
| US20070116672A1 (en) | 2003-09-05 | 2007-05-24 | Kotwal Girish J | Treatment of rheumatic diseases |
| US7348401B2 (en) | 2003-09-10 | 2008-03-25 | Innate Biotech, Inc. | Peptides that inhibit complement activation |
| PT1713503E (pt) | 2004-02-10 | 2013-11-14 | Nat Jewish Health | Inibição do factor b, a via alternativa do complemento e métodos relacionados |
| DK2860251T3 (en) | 2004-02-12 | 2018-06-06 | Archemix Llc | APTAPMER PHARMACEUTICALS USEFUL IN TREATMENT OF COMPLEMENT-RELATED DISEASES |
| WO2005110374A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component |
| US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| CN1950095A (zh) | 2004-05-10 | 2007-04-18 | 诺瓦西股份有限公司 | 用活性的维生素d化合物预防动脉再狭窄 |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
| US8043609B2 (en) | 2004-10-08 | 2011-10-25 | Potentia Pharmaceuticals, Inc. | Viral complement control proteins for eye disorders |
| WO2006042252A2 (en) | 2004-10-08 | 2006-04-20 | Potentia Pharmeceuticals, Inc. | Viral complement control proteins for eye disorders |
| ATE528410T1 (de) | 2004-11-18 | 2011-10-15 | Univ Yale | Verfahren und zusammensetzungen zur diagnose von altersbedingter maculadegeneration |
| ATE526421T1 (de) | 2005-02-14 | 2011-10-15 | Univ Iowa Res Found | Verfahren und reagenzien zur behandlung und diagnose von altersbedingter makuladegeneration |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| US20090117171A1 (en) | 2005-03-11 | 2009-05-07 | Cedric Francois | Compositions and methods for treatment of macular degeneration and related conditions |
| BRPI0617186A2 (pt) | 2005-10-08 | 2011-07-19 | Potentia Pharmaceuticals Inc | uso de análogo de compstatina, implante ocular, micropartìcula ou nanopartìcula, composição, composto multivalente, ácido nucléico, vetor de expressão, célula hospedeira recombinante, proteìna de fusão e método de produção e teste |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| KR20130137716A (ko) | 2005-11-04 | 2013-12-17 | 제넨테크, 인크. | 안질환 치료를 위한 보체 경로 억제제의 용도 |
| ES2677619T3 (es) | 2005-11-28 | 2018-08-03 | The Trustees Of The University Of Pennsylvania | Análogos potentes de la compstatina |
| KR20080087814A (ko) | 2005-12-22 | 2008-10-01 | 알콘 리서치, 리미티드 | 보체 인자 ｈ의 위험 변이체가 있는 환자에서 연령 관련황반변성의 예방 및 치료를 위한 ｃ3-전환효소 저해제 |
| US20070196367A1 (en) | 2006-02-22 | 2007-08-23 | Valentin Dinu | Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system |
| CA2658015A1 (en) | 2006-03-30 | 2007-10-11 | Diatos S.A. | Camptothecin-peptide conjugates and pharmaceutical compositions containing the same |
| AU2008214359B2 (en) | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
| EP2167103B1 (en) | 2007-07-19 | 2017-03-01 | Allexcel, Inc. | Self-assembling amphiphilic polymers as anticancer agents |
| WO2009015087A2 (en) | 2007-07-20 | 2009-01-29 | Potentia Pharmaceuticals, Inc. | Compositions and methods for treatment of trauma |
| CN101854916A (zh) * | 2007-10-02 | 2010-10-06 | 博泰迪亚制药公司 | 由凝胶持续递送坎普他汀类似物 |
| US8521273B2 (en) | 2008-01-29 | 2013-08-27 | Gilbert H. KLIMAN | Drug delivery devices, kits and methods therefor |
| EP2278987A4 (en) | 2008-03-28 | 2012-08-22 | Apellis Ag | MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM |
| NO2424557T3 (enExample) | 2009-05-01 | 2018-03-24 | ||
| US9291622B2 (en) | 2009-05-21 | 2016-03-22 | Apellis Pharmaceuticals, Inc. | Complement assays and uses thereof |
| EP2338520A1 (de) | 2009-12-21 | 2011-06-29 | Ludwig Maximilians Universität | Konjugat mit Zielfindungsligand und dessen Verwendung |
| US8468925B2 (en) | 2010-05-06 | 2013-06-25 | Warwick Mills Inc. | Suicide bomber blast threat mitigation system |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| US20130324482A1 (en) | 2010-07-09 | 2013-12-05 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of rhinosinusitis and nasal polyposis |
| WO2012040259A2 (en) | 2010-09-23 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Modified compstatin with improved stability and binding properties |
| CN107050422B (zh) | 2011-05-11 | 2021-11-09 | 阿佩利斯制药公司 | 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途 |
| MX379206B (es) * | 2011-06-22 | 2025-03-10 | Apellis Pharmaceuticals Inc | Uso de inhibidores del complemento en trastornos crónicos. |
| CN110229216B (zh) | 2011-09-07 | 2023-06-16 | 宾夕法尼亚州大学理事会 | 具有改善的药代动力学性质的坎普他汀类肽 |
| WO2014028861A1 (en) | 2012-08-17 | 2014-02-20 | Apellis Pharmaceuticals, Inc. | Detection of high risk drusen |
| US20160194359A1 (en) * | 2012-11-15 | 2016-07-07 | Apellis Pharmaceuticals, Inc. | Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods |
| PT3660033T (pt) | 2012-11-15 | 2021-07-06 | Apellis Pharmaceuticals Inc | Análogos de compstatina de longa ação e composições e métodos relacionados |
| WO2014100407A1 (en) | 2012-12-19 | 2014-06-26 | The Regents Of The University Of California | Compstatin analogs |
| US10308687B2 (en) * | 2013-03-15 | 2019-06-04 | Apellis Pharmaceuticals, Inc. | Cell-penetrating compstatin analogs and uses thereof |
| JP6159886B2 (ja) | 2013-07-16 | 2017-07-05 | 北京机械▲設▼▲備▼研究所 | 高層及び超高層ビルの消火活動に適用する消防車 |
-
2006
- 2006-10-06 US US11/544,389 patent/US8168584B2/en active Active
-
2007
- 2007-01-19 AU AU2007207385A patent/AU2007207385B2/en not_active Ceased
- 2007-01-19 DK DK07718112.1T patent/DK1993673T3/en active
- 2007-01-19 PL PL07718112T patent/PL1993673T3/pl unknown
- 2007-01-19 US US12/161,410 patent/US20090220572A1/en not_active Abandoned
- 2007-01-19 JP JP2008551458A patent/JP2009523821A/ja active Pending
- 2007-01-19 EP EP07718112.1A patent/EP1993673B1/en active Active
- 2007-01-19 WO PCT/US2007/001649 patent/WO2007084765A2/en not_active Ceased
- 2007-01-19 ES ES07718112.1T patent/ES2644752T3/es active Active
-
2012
- 2012-03-01 US US13/409,941 patent/US9056076B2/en active Active
-
2013
- 2013-04-11 AU AU2013203946A patent/AU2013203946C1/en not_active Ceased
- 2013-04-17 JP JP2013086862A patent/JP2013155189A/ja active Pending
-
2015
- 2015-05-06 US US14/705,592 patent/US20160060297A1/en not_active Abandoned
- 2015-06-18 US US14/744,019 patent/US20160015810A1/en not_active Abandoned
- 2015-09-11 JP JP2015179993A patent/JP2016028081A/ja active Pending
-
2017
- 2017-01-06 US US15/400,831 patent/US10407466B2/en active Active